You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Ironwood’s drug for IBS with constipation gets regulatory approval in Europe

Ironwood Pharmaceuticals Inc. of Cambridge and its European partner Almirall S.A. said Wednesday that Ironwood’s drug for irritable bowel syndrome with constipation has been approved by European regulators.

That same drug is about to go onto the US market, following approval by the Food and Drug Administration earlier this year. According to a recent Globe story, irritable bowel syndrome, or IBS, afflicts 30 million to 40 million Americans. Given the number of people affected, the drug has the potential to be a blockbuster, ringing up annual sales of $1 billion or more.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week